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Abstract A wide variation of deﬁnitions of recurrent
disease and survival are used in the analyses of outcome of
patients with early breast cancer. Explicit deﬁnitions with
details both on endpoints and censoring are provided in less
than half of published studies. We evaluated the effects of
various deﬁnitions of survival and recurrent disease on
estimated outcome in a prospectively determined cohort of
463 patients with primary breast cancer. Outcome esti-
mates were determined both by the Kaplan–Meier and a
competing risk method. In- or exclusion of contralateral
breast cancer or non-disease related death in the deﬁnition
of recurrent disease or survival signiﬁcantly affects esti-
mated outcome probability. The magnitude of this ﬁnding
was dependent on patient-, tumour-, and treatment char-
acteristics. Knowledge of the contribution of non-disease
related death or contralateral breast cancer to estimated
recurrent disease rate and overall death rate is indispens-
able for a correct interpretation and comparison of outcome
analyses.
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Introduction
In studies on early breast cancer, outcome is usually de-
ﬁned as the time from diagnosis or surgery until a partic-
ular event of interest (endpoint). The event of interest can
vary and may include death (overall survival), disease re-
lated death (disease speciﬁc survival), or recurrent disease
(disease free survival).
Altman et al. systematically reviewed the appropriate-
ness of the application and presentation of survival
analysis in clinical oncology journals [1]. They found that
among papers speciﬁcally dealing with death as an end-
point; only 47% explicitly described this end-point as
either any death or only cancer-related death. In as much
as 61% of papers that studied time to progressive disease
the handling of non-cancer related mortality was not
clearly deﬁned.
In studies on patients with early breast cancer a wide
variation of deﬁnitions of disease free survival have been
used. These deﬁnitions always included local recurrence,
regional recurrence, and distant metastasis, but some-
times also included non-disease related death, contralat-
eral breast cancer and in some cases second primary
cancer. For example, the 1998 overview of randomised
trials on adjuvant therapy included contralateral breast
cancer in the analysis of disease recurrence, but did not
include non-disease related death [2]. In the NSABP B14
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eral breast cancer, and second primary cancer were in-
cluded as events in the deﬁnition of disease free survival
[3, 4]. In a recent report with long-term ﬁndings the
deﬁnition of recurrence free survival was restricted to
local or regional recurrence, or distant metastasis only
[5].
Despite these different deﬁnitions, many papers on
breast cancer survival do not provide an explicit deﬁni-
tion of recurrent disease. A review on prognostic factors
in node-negative breast cancer was published in 2002 by
Mirza et al. [6]. In the methods section of their report,
they stated that only papers in which overall or disease
free survival were speciﬁed were included in their re-
view. Sixty-three papers from their reference list dealt
with survival analysis in primary breast cancer. We re-
viewed the deﬁnitions of recurrent disease used in these
63 papers. In only 21 out of 47 papers that studied time
to recurrent disease the deﬁnition of recurrent disease
explicitly described the handling of non-cancer related
mortality. Intercurrent deaths were censored in 14 papers
and counted as events in 7 papers. Eight papers explicitly
described the handling of contralateral breast cancer.
Contralateral breast cancer was censored in 1 and con-
sidered as event in 7 papers. The handling of second
primary cancer was described in 7 papers. Second pri-
mary cancer was censored in 2 and counted as event in 5
papers.
In most papers the survival probability is estimated with
the Kaplan–Meier method from observed survival times,
censored or uncensored [7]. Censoring may arise due to
end of follow-up, loss to follow-up, but also due to a
competing event. The Kaplan–Meier method requires non-
informative censoring, which means that those individuals
who are censored should be as likely to have the sub-
sequent event of interest as those who remain in the study.
In particular competing events, such as: contralateral breast
cancer or non-disease related death, might cause informa-
tive censoring. For this reason others have propagated an
approach that accounts for informative censoring in sur-
vival analyses in the presence of competing events, a
competing risk analysis [8–11].
The main objective of this study is to analyse the effect
of various deﬁnitions of survival and relapse on prediction
of outcome in patients with early breast cancer. Thereby,
we focus on the inﬂuences of non-disease related death
and contralateral breast cancer. Data from a (prospec-
tively determined) cohort of 463 patients with primary
breast cancer were used to evaluate the effects of various
deﬁnitions of survival and relapse. A second objective
was to compare the value of competing risk analysis with
that to that of the Kaplan–Meier method for survival
analysis.
Material and methods
Between October 1989 and March 1993 463 patients
diagnosed with operable, stage I to III breast cancer agreed
to participate in a prospective registration study on prog-
nostic factors. We obtained written informed consent from
all patients. Surgery, radiotherapy and adjuvant systemic
treatment were given according to the guidelines of the
Comprehensive Cancer Centre Middle Netherlands. Pa-
tient-, tumour- and treatment characteristics are shown in
Table 1. We assessed follow-up data until December 2002.
The events that were used to determine the different
deﬁnitions of outcome were local- and regional recurrent
disease, contralateral breast cancer, distant metastasis,
disease related death and non-disease related death. In the
various analyses these events were either ignored, consid-
ered as event of interest or as competing event (censored),
depending on the various deﬁnitions of outcome. Deﬁni-
tions of overall survival, diseases speciﬁc survival, disease
free interval, and disease free survival are given in Table 2.
We deﬁned local recurrent disease as either recurrence in
the skin or soft tissue of the (ipsilateral) chest wall or in the
ipsilateral breast. Regional recurrent disease conﬁned
recurrence in the lymph nodes in the ipsilateral axilla, in-
fraclavicular fossa or internal mammary chain. Contralat-
eral breast cancer included invasive breast cancer lesions in
the contralateral breast regardless of histological type,
lymph node involvement, and time interval from initial
Table 1 Patient-, tumour-, and treatment characteristics
Number of patients (%)
Age
£50 year 142 (31)
51–70 year 213 (46)
>70 year 108 (23)
Primary surgical therapy
Breast conserving therapy 266 (57)
Modiﬁed radical mastectomy 190 (41)
Other 7 (2)
Adjuvant systemic therapy
Hormonal therapy 142 (31)
Chemotherapy 72 (16)
Histology
Ductal 290 (63)
Other 173 (37)
Tumour size
£ 20 mm 272 (59)
> 20 mm 191 (41)
Axillary lymph nodes
Negative 278 (60)
Positive 185 (40)
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123therapy or from subsequent recurrent disease. Breast cancer
lesions at any other site, including the ipsilateral supra-
clavicular lymph nodes, were classiﬁed as distant metas-
tases. We classiﬁed death as disease related when death
occurred in patients known with distant metastases.
Otherwise we classiﬁed death as non-disease related.
Survival probabilities were determined both by Kaplan–
Meier method [7], and by competing risk analyses [8].
Competing risk analyses were calculated as described in
‘‘Tutorial in biostatistics: competing risks and multi-state
models’’ by Putter et al. [8].
Results
During median 10 years of follow-up 149 patients died.
About 91 deaths were related to breast cancer, and another
58 patients died from causes unrelated to breast cancer.
Local recurrences were diagnosed in 28 patients, regional
recurrences in another 24. Distant metastases occurred in
111 patients, and in 30 patients breast cancer was diag-
nosed in the contralateral breast. Estimated with the Kap-
lan–Meier method, after 10 years of follow-up 68% of
patients were still alive (overall survival). If no one had
died from causes other than breast cancer, 79% of
patients would have been alive (disease-speciﬁc survival)
(Table 3). Disease free survival varied between 56% and
59%, depending on the deﬁnition of relapse. If no patients
had died during follow-up, 65–69% of patients would have
been free of recurrent disease (disease free interval)
(Table 3). Compared with the competing risk approach, the
Kaplan–Meier method slightly underestimated 10-year
survival rates when one or more competing events were
censored instead or ignored. The largest difference (2.0
percent-point) was found when both non-disease related
death and contralateral breast cancer were censored
(Table 3).
Non-disease related death
The difference in estimated survival probability between
overall survival and disease speciﬁc survival and between
disease free survival and disease free interval is by deﬁ-
nition caused by the handling of non-disease related death.
As older age is associated with a higher probability of non-
disease related death, we evaluated the effect of patient’s
Table 2 Deﬁnitions of outcome.
Overall survival Time from surgery until death from any cause
Disease speciﬁc survival Time from surgery until death related to breast cancer. Death not related to breast cancer
is censored (Kaplan–Meier analysis) or treated as competing event (competing risk analysis).
Disease free interval Time from surgery until recurrent disease.
a Death not related to breast cancer is censored
(Kaplan–Meier analysis) or treated as competing event (competing risk analysis).
Disease free survival Time from surgery until recurrent disease
a or death from any cause.
a In the deﬁnition of recurrent disease local recurrence, regional recurrence, and distant metastasis are considered events; contralateral breast
cancer is ignored, treated as event or censored (Kaplan–Meier analysis) / treated as competing event (competing risk analysis)
Table 3 Estimated 10-year survival according to deﬁnition of survival determined both by Kaplan–Meier method and the competing risk
analysis.
Survival deﬁnition 10-year Survival (%)
All patients No adjuvant systemic therapy Adjuvant systemic therapy
KM CR KM CR KM CR
Overall survival 68.0 75.8 58.6
Disease speciﬁc survival 79.3 80.6 85.3 86.2 71.9 73.7
Disease free survival
Contralateral BC ignored 59.3 65.8 51.2
Contralateral BC censored 58.6 59.4 64.9 66.0 51.1 51.6
Contralateral BC event 55.5 59.9 50.2
Disease free interval
Contralateral BC ignored 69.4 70.9 74.6 75.8 63.0 64.9
Contralateral BC censored 68.9 70.9 73.9 75.9 63.2 65.4
Contralateral BC event 64.8 66.5 67.6 69.2 61.3 63.4
KM: Kaplan–Meier method; CR: competing risk analysis; BC: breast cancer
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123age on estimated survival probability using the various
deﬁnitions of survival. As shown in Table 4, patients aged
more than 70 years were at risk for dying from a cause
unrelated to breast cancer, whereas patients aged 50 years
or less seldom died from a cause unrelated to breast cancer.
As a consequence, in the younger subgroup 10-year overall
survival was almost equal to 10-year disease speciﬁc sur-
vival. Whereas in the elderly, estimated 10-year disease
speciﬁc survival was more than 30% point better than
estimated 10-year overall survival (Fig. 1). In the younger
subgroups differences between Kaplan–Meier and com-
peting risk estimates were limited (£1%). In the elderly
estimations of 10-year disease speciﬁc survival were 82.2%
and 84.9% with Kaplan–Meier and competing risk analy-
ses, respectively. Estimations of 10-year disease free
interval were 73.6% and 77.6% respectively for two sta-
tistical methods.
Contralateral breast cancer
We evaluated the effect of the inclusion of contralateral
breast cancer as event in the analysis of disease recurrence
on estimated disease free interval and disease free survival
(Table 3). The administration of adjuvant systemic therapy
is known to reduce the risk of contralateral breast cancer
[12, 13]. In the whole study population the absolute
reduction in disease free survival or disease free interval
due to inclusion of contralateral breast cancer as event in
the deﬁnition of relapse was approximately 4%; in patients
not treated with adjuvant systemic therapy 6–7%, and in
patients treated with adjuvant systemic therapy 1–2%. In
the broadest deﬁnition of relapse 197 events were counted
during 10-years follow-up, including 47 non-disease re-
lated deaths and 26 contralateral breast cancers. That is, in
the analysis of disease free interval 17% of events were
contralateral breast cancers, compared with 13% in the
analysis of disease free survival. Consequently, the effect
of the inclusion of contralateral breast cancer as event in
the deﬁnition of relapse was greater when estimating dis-
ease free interval than when estimating disease free sur-
vival (Table 3).
Similarly, the greatest effect of the inclusion of contra-
lateral breast cancer and non-disease related death as
events on estimated disease recurrence rate was found in
patients with low risk breast cancer. In a subgroup of 168
patients with T1N0 breast cancer, not treated with adjuvant
systemic therapy, the 10-year relapse rate including local
relapse, regional relapse, or distant metastasis was 23%.
The estimated 10-year relapse rate rose to 31% both with
the inclusion of either contralateral breast cancer or non-
disease related death as event in the deﬁnition of relapse,
and to 38% with the inclusion of both events in the deﬁ-
nition of relapse.
Discussion
In the present study we show that the inclusion of contra-
lateral breast cancer or non-disease related death as event
in the deﬁnition of recurrent disease or survival of early
breast cancer signiﬁcantly affects estimated outcome
probability. The magnitude of the effect depends on pa-
tient-, tumour-, and treatment characteristics. The greatest
effect was observed for the handling of non-disease related
death within the group of patients older than 70 years, and
for the inclusion of contralateral breast cancer as event in
patients with low risk breast cancer not treated with adju-
vant systemic therapy.
These ﬁndings stress the importance of a clear deﬁnition
and reporting of outcome parameters in scientiﬁc papers
presenting the results of phase III randomized trials.
However, the magnitude of the observed effects can differ
depending on the various events that have been included,
ignored or censored in the deﬁnition of outcome. As a
consequence, the in- or exclusion of contralateral breast
cancer or non-disease related death in the deﬁnition of
Table 4 Estimated 10-year event rate according to age at diagnosis determined both by Kaplan–Meier method and competing risk analysis.
Event 10-year Event rate (%)
£ 50 yr 51–70 yr > 70 yr
KM CR KM CR KM CR
Overall death 31.1 23.5 52.0
Disease related death 28.6 28.1 16.4 15.7 17.7 15.1
Non-disease related death 3.6 3.0 8.5 7.8 41.7 36.9
Recurrent disease or death 41.5 32.2 58.7
Recurrent disease 39.5 38.8 26.8 25.8 26.3 22.4
Death without recurrent disease 3.2 2.7 7.5 6.5 43.8 36.2
KM: Kaplan–Meier method; CR: competing risk analysis. Recurrent disease was deﬁned as either local recurrence, regional recurrence or distant
metastasis whichever came ﬁrst. Occurring contralateral breast cancer was ignored
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123outcome could inﬂuence the results of a trial. We can
illustrate this with data from the Anastrozole, Tamoxifen,
Alone or in Combination (ATAC) trial, in which 6241
patients were included in the 2 relevant arms of this trial
[12, 13]. After a median follow-up of 68 months, 831 pa-
tients have died (411 patients treated with anastrozole and
420 patients treated with tamoxifen). More patients who
were treated with tamoxifen died from breast cancer than
patients who were treated with anastrozole (265 vs. 235),
whereas fewer patients who received tamoxifen died from
a cause not related to breast cancer (155 vs. 176). Treat-
ment with anastrozole also led to a reduction in disease
recurrences (402 vs. 498). A considerable part of this
reduction was caused by the difference in occurrence of
contralateral breast cancers (35 vs. 59). Consequently,
anastrozole led to an improvement in disease free survival
(Hazard Rate (HR) 0.87, P = 0.01), and an even better
improvement in disease free interval (HR 0.79,
P = 0.0005). Overall survival was similar for anastrozole
and tamoxifen treated patients (HR 0.97), whereas disease
speciﬁc survival was 12% better in the anastrozole group,
although this was not signiﬁcant (HR 0.88, P = 0.20).
These data from the ATAC trial illustrate that a clear
deﬁnition of survival endpoints, including the contribution
of non-disease related death and the contribution of con-
tralateral breast cancer to the estimated disease recurrence
rate are crucial for a correct interpretation of outcome
analyses in clinical trials. These data also demonstrate that
a signiﬁcant difference in disease free survival is not
automatically followed by a signiﬁcant difference in
overall survival.
The Kaplan–Meier method for estimating survival has
repeatedly been criticised for possible biases in the esti-
mation of event rates [8, 9, 11, 14]. In the presence of
competing events, cumulative incidence functions of the
events of interest are probably evaluated more appropri-
ately by taking into account other events within a com-
peting risk framework. In general, event rates derived using
the Kaplan–Meier approach are larger than estimates
accounting for competing risks, [8, 9, 11] and differences
between Kaplan–Meier and competing risk approaches can
become substantial when the competing risk event is re-
lated to or is a result of the underlying disease. But, as
presented by Satagopan et al. ignoring the informative
censoring mechanism does not substantially inﬂuence the
estimates of breast cancer-speciﬁc mortality [15]. We
present similar results in our estimations of disease-speciﬁc
survival and disease free survival. However, differences
became more substantial when relatively more patients
were censored due to competing events. Although not the
subject of our current analyses, it is probably more likely
that ignoring of the informative censoring mechanism will
substantially inﬂuence the estimates of local recurrence.
Conclusion
Clear deﬁnitions of endpoints and competing events are
crucial for the correct interpretation and reliable compari-
son of outcome studies. In the present study on patients
with early breast cancer, the inclusion of contralateral
breast cancer and/or non-disease related death substantially
inﬂuenced estimates of recurrent disease rate and survival,
speciﬁcally in elder patients and patients with a good
prognosis. Bias generated by the Kaplan–Meier approach
due to informative censoring of contralateral breast cancer
or non-disease related death was limited.
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